COMPASS Pathways Plc Sponsored ADR (CMPS)

32.22
0.08 0.25
NASDAQ
Prev Close 32.30
Open 31.97
Day Low/High 31.78 / 32.68
52 Wk Low/High 28.58 / 61.69
Volume 228.59K
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Once They Uplist I Want to Own Cybin and Draganfly

Once They Uplist I Want to Own Cybin and Draganfly

What they both have in common is a ton of momentum in their respective businesses.

Here's My List of Billion Dollar Bets

Here's My List of Billion Dollar Bets

Let's look at seven names that you can buy right now and watch grow.

As the Focus on Psychedelic Stocks Increases, So Do the Valuations

As the Focus on Psychedelic Stocks Increases, So Do the Valuations

The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations.

Let's Put COMPASS Pathways in the Watch but Not Act Yet Category

Let's Put COMPASS Pathways in the Watch but Not Act Yet Category

CMPS may be a company representing the true cannabis 2.0. The irony in that is it isn't a cannabis company but rather a play on psilocybin.

Psychedelic Industry Setting Up For an Even Bigger 2021

Psychedelic Industry Setting Up For an Even Bigger 2021

Dealmaking is going strong and looks set to continue as mental health becomes a key investment theme going forward.

Analyst Bets Compass' 'Magic Mushroom' Approach Is on the Button

Analyst Bets Compass' 'Magic Mushroom' Approach Is on the Button

Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target.

Compass Pathways Takes Investors on a Trip to Higher Prices

Compass Pathways Takes Investors on a Trip to Higher Prices

Fresh off IPO, company sees mushrooming opportunity in psilocybin.